Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 4478
Sealed predictions
- FBN2 in dopamine neurons, braak+0.11 (p 0.775) → +0.84 (p 0.005)receipt 4483
Swarm cases
receipt 4483: FBN2 in dopamine neurons, braak
- power
- full sample +0.48 (p 0.042, n 18), 95% CI +0.02 to +0.78. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.45 (p 0.063, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.44 (p 0.070, n 18). could be the mix.
- skeptic
- leave-one-out range +0.41 to +0.63, sign flips 0; without severely affected donors +0.48 (p 0.042, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FBN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts